The Best Path Through Found's Plans Without Insurance (2026) | Luma Health
Cost & Access · 2026

Navigating Found's Plans
Without Insurance

Quick Verdict

Found's multi-tier structure (compounded, branded, non-GLP-1) is built with insurance navigation in mind; without insurance, a flat-rate compounded provider is typically simpler and less expensive.

Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) are priced the same whether or not you have insurance.

Found's plan tiers make the most sense when insurance is part of the equation — helping patients access brand-name medication through coverage. Without insurance in the picture, the calculation changes considerably.

What Found's Tiers Mean for Cash-Pay Patients

Without insurance, the branded-medication tier isn't particularly useful, since you'd be paying brand-name cash-pay pricing (often $1,000+/month) rather than a copay. That leaves the compounded tier as the more relevant option for cash-pay patients, plus whatever separate membership fee and potential lab costs apply on top.

Why Flat-Rate Pricing Is Simpler Without Insurance

A flat-rate compounded provider doesn't need multiple tiers, since there's no insurance billing complexity to navigate — the same price applies to every cash-pay patient regardless of coverage status. Luma Health's compounded semaglutide is $197/month and tirzepatide is $297/month, flat, with no separate membership or lab fee layered on top for most patients.

The Question Worth Asking

If you know upfront that you're paying cash regardless of outcome, ask whether a multi-tier program's insurance-navigation features are actually saving you anything. If they're not (because you're not using insurance at all), a program built specifically for cash-pay simplicity may serve you better than one built around insurance coordination you won't use.

What a Focused Cash-Pay Provider Still Includes

A real medical evaluation, ongoing provider access for dose adjustments and side-effect questions, and shipping remain the core of any legitimate GLP-1 program, cash-pay or insurance-based. Choosing a focused cash-pay provider doesn't mean sacrificing the clinical fundamentals — it means not paying for insurance-navigation infrastructure you won't use.

Which Fits You Without Insurance

Found's tiers may still fit if you…
  • Want the option to try insurance-covered brand medication later
  • Value its coaching and community features regardless of insurance
  • Are comfortable navigating multiple plan tiers
A flat-rate provider fits if you…
  • Know you're paying cash regardless of outcome
  • Want the simplest possible single price
  • Don't need bundled coaching or insurance-navigation features

Built for
cash-pay simplicity

Compounded semaglutide at $197/month or tirzepatide at $297/month — one price, whether or not you have insurance.

Get Started → Or start your free health assessment

Frequently Asked Questions

It can be, particularly for its coaching and community features, but its multi-tier structure is primarily built with insurance navigation in mind — without insurance, a flat-rate provider is often simpler and less expensive.

This depends on your specific plan and medication; membership and medication may be billed separately, and lab costs can apply on top depending on your intake results.

No. A real medical evaluation and ongoing provider access are the core of any legitimate program, regardless of whether it's structured around cash-pay simplicity or insurance navigation.

That's a reasonable consideration if you expect coverage changes soon. If your insurance situation is stable and you know you're paying cash, that flexibility may not add practical value for you.

Yes, when both prescribe compounded semaglutide or tirzepatide, the active ingredient is the same. What differs is pricing structure and program features.

Start your new provider's evaluation while you still have some current medication, share your treatment history, and cancel Found once your new prescription is confirmed.

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
  2. Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com
Medical Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Individual results and needs vary; consult a licensed healthcare provider before starting, stopping, or changing any treatment or supplement. This article reflects information available as of July 2026. Luma Health's compounded medications are not themselves FDA-approved as finished drug products; their active ingredients are FDA-approved in commercial formulations such as Ozempic, Wegovy, Mounjaro, and Zepbound.